AstraZeneca-Fusion deal reignites radiopharma space

seekingalpha03-19

Companies focused on radiopharmaceuticals traded higher on Tuesday after AstraZeneca (AZN) agreed to acquire its partner Fusion Pharma (NASDAQ:FUSN), marking the latest M&A deal for a highly popular ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2420253842?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1389510306/image_1389510306.jpg","is_english":true,"pubTime":"2024-03-19 20:19","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2420253842","market":"fut","top_or_hot":-1,"title":"AstraZeneca-Fusion deal reignites radiopharma space","media":"seekingalpha","content":"<div>\n<p>Companies focused on radiopharmaceuticals traded higher on Tuesday after AstraZeneca (AZN) agreed to acquire its partner Fusion Pharma (NASDAQ:FUSN), marking the latest M&A deal for a highly popular ...</p>\n\n<a href=\"https://seekingalpha.com/news/4080965-fusion-pharma-stock-jumps-astrazeneca-hunts-radiopharma\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AstraZeneca-Fusion deal reignites radiopharma space</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAstraZeneca-Fusion deal reignites radiopharma space\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-03-19 20:19 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4080965-fusion-pharma-stock-jumps-astrazeneca-hunts-radiopharma><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Companies focused on radiopharmaceuticals traded higher on Tuesday after AstraZeneca (AZN) agreed to acquire its partner Fusion Pharma (NASDAQ:FUSN), marking the latest M&A deal for a highly popular ...</p>\n\n<a href=\"https://seekingalpha.com/news/4080965-fusion-pharma-stock-jumps-astrazeneca-hunts-radiopharma\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1267930730.SGD","symbol_name":"富兰克林美国机遇基金AS Acc SGD (CPF)","start_time":0,"source_url":"https://seekingalpha.com/news/4080965-fusion-pharma-stock-jumps-astrazeneca-hunts-radiopharma","article_id":"2420253842","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1389510306/image_1389510306.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2420253842","pubTimestamp":1710850787,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Companies focused on radiopharmaceuticals traded higher on Tuesday after AstraZeneca (AZN) agreed to acquire its partner Fusion Pharma (NASDAQ:FUSN), marking the latest M&A deal for a highly popular d","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1267930730.SGD":"富兰克林美国机遇基金AS Acc SGD (CPF)","BK4578":"CAR-T","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","NVSEF":"Novartis AG","BCYC":"Bicycle Therapeutics Limited","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","BK4568":"美国抗疫概念","CASI":"凯信远达","PNT":"POINT BIOPHARMA GLOBAL INC","LU1670710588.SGD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (SGD) ACC","BK4198":"医疗保健用品","CATX":"Perspective Therapeutics","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","LU1623119135.USD":"Natixis Mirova Global Sustainable Equity R-NPF/A USD","LU2265009873.SGD":"Eastspring Investments - Global Growth Equity AS SGD-H","LU1670710661.SGD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (SGD) INC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU1712237335.SGD":"Natixis Mirova Global Sustainable Equity H-R-NPF/A SGD","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","RYZB":"RayzeBio, Inc.","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","FUSN":"Fusion Pharmaceuticals Inc.","LU1670711123.USD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (USD) INC","NVS":"诺华","ATNM":"Actinium Pharmaceuticals, Inc.","BAYRY":"Bayer A.G.","LLY":"礼来","TLPPF":"Telix Pharmaceutical Ltd.","LU0466842654.USD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"A\" (USD) ACC","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU0097036916.USD":"贝莱德美国增长A2 USD","LU0320765059.SGD":"FTIF - Franklin US Opportunities A Acc SGD","LU1032466523.USD":"高盛全球多资产收益组合Acc","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","LU1670711040.USD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (USD) ACC","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","AZN":"阿斯利康","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","PNT.AU":"PANTHER METALS LTD","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","LNTH":"Lantheus Holdings, Inc.","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU2602419157.SGD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"AC\" (SGD) ACC","BK4585":"ETF&股票定投概念","CLRB":"Cellectar Biosciences Inc.","BK4139":"生物科技","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BMY":"施贵宝"},"translate_title":"阿斯利康—Fusion交易重燃放射性药物空间","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AZN":1,"TLPPF":1,"RYZB":1,"PNT.AU":1,"PNT":1,"NVSEF":1,"NVS":1,"LNTH":1,"LLY":1,"FUSN":1,"CLRB":1,"CASI":1,"ATNM":1,"BAYRY":1,"BCYC":1,"CATX":1,"BMY":1},"content_text":"Companies focused on radiopharmaceuticals traded higher on Tuesday after AstraZeneca (AZN) agreed to acquire its partner Fusion Pharma (NASDAQ:FUSN), marking the latest M&A deal for a highly popular drug class. The British drugmaker has partnered with Fusion (FUSN) since 2020, and its M&A offer, which indicates a $21.00 per share in cash plus a deal sweetener, implies a total transaction value of $2.4B for the Canadian biotech. The deal’s 97% premium indicates big pharma’s rising interest in radiopharmaceuticals. The global market for radiopharma is expected to reach more than $13B by 2032 with over 10% CAGR, according to Precedence Research, a global provider of market insights. While Swiss drugmaker Novartis (NVS) (OTCPK:NVSEF) is a dominant player in the radiopharma space with its cancer drugs Pluvicto and Lutathera, others are catching up. In December, Eli Lilly (LLY) closed its $1.4B acquisition of Point Biopharma Global (PNT), a biotech focused on radioligand therapies.  Last month, Bristol Myers (BMY) acquired RayzeBio (RYZB), a developer of clinical-stage radiopharmaceuticals, for $4.1B, outbidding at least two other significant offers from rivals. In May 2023, German conglomerate Bayer (OTCPK:BAYRY) partnered with Bicycle Therapeutics (BCYC) to develop a new class of radiopharmaceuticals called Bicycle radioconjugates for cancer. The AZN-FUSN deal has reignited interest in the radiopharma space. While Fusion (FUSN) climbed more than 100% in the premarket, its peers Perspective Therapeutics (CATX), Actinium Pharmaceuticals (ATNM), and Cellectar Biosciences (CLRB) have also made notable gains after the news. Other drug developers focused on radiopharmaceuticals include Lantheus Holdings (LNTH), CASI Pharmaceuticals (CASI), and Telix Pharma (OTCPK:TLPPF).  More on Fusion Pharmaceuticals  Fusion Pharmaceuticals' Partnerships Strengthen Long-Term Outlook Biggest stock movers today: FUSN, NCMI, crypto stocks and more AstraZeneca will buy Fusion Pharmaceuticals for ~$2B Seeking Alpha’s Quant Rating on Fusion Pharmaceuticals Historical earnings data for Fusion Pharmaceuticals","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2420253842"}